# US 2020/0390832 A1 · Composition for use in the treatment and/or improvement of sleep and mood disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390832 A1
- Document ID: US20200390832A1
- Status: Published application
- Kind: A1
- Application number: 16/769,526
- Filed: 2018-12-19
- Published: 2020-12-17
- Earliest claimed: 2017-12-19
- Assignees: Probiotical S.P.A.
- Applicants: Probiotical S.P.A.
- Inventors: Marco PANE; Angela AMORUSO; Mirta FIORIO; Angela MAROTTA; Giovanna FELIS; Antonio DEL CASALE
- Web page: https://patentgrep.com/patent/US20200390832A1

## CPC

- A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 35/745: Bifidobacteria
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention refers to a composition for use in the treatment of sleep disorder, in particular, in the improvement of sleep quality. Furthermore, the present invention refers to a composition for use in the treatment of mood modulation

## Claims

### Claim 1

A composition (C) comprising, a or alternatively, consisting of:
(a) a bacteria strains mixture (M) comprising or, alternatively, consisting of at least one bacteria strain selected from among the group comprising or, alternatively, consisting of:
(a-i) a bacterium strain of the Lactobacillus fermentum species identified as the Lactobacillus fermentum LF16 DSM 26956 bacterium strain; and/or
(a-ii) a bacterium strain of the Lactobacillus plantarum species identified as the Lactobacillus plantarum LP01 LMG P-21021 bacterium strain; and/or
(a-iii) a bacterium strain of the Lactobacillus plantarum species identified as the Lactobacillus plantarum LP02 LMG P-21020 bacterium strain; and/or
(a-iv) a bacterium strain of the Lactobacillus rhamnosus species identified as the Lactobacillus rhamnosus LR06 DSM 21981 bacterium strain; and/or
(a-v) a bacterium strain of the Bifidobacterium longum species identified as the Bifidobacterium longum BL04 DSM 23233 bacterium strain; and, optionally,
(b) at least one technological additive and/or at least one pharmaceutical or food grade excipient,
said composition (C) being for use in a method for curative and/or preventive treatment of mood modulation or mood dysregulation.

### Claim 2 (depends on 1)

The composition (C) for use according to claim 1, wherein said composition is for use in a method for treating a mood instability over time, preferably in a method for treating mood stabilisation over time or mood state at a state leaning towards optimism.

### Claim 3 (depends on 1)

The composition (C) for use according to claim 1, wherein said (a) bacteria strains mixture (M) comprises or, alternatively, consists of:
(a-i) a bacterium strain of the Lactobacillus fermentum species identified as the Lactobacillus fermentum LF16 DSM 26956 bacterium strain; and
(a-ii) a bacterium strain of the Lactobacillus plantarum species identified as the Lactobacillus plantarum LP01 LMG P-21021 bacterium strain, and/or;
(a-iii) a bacterium strain of the Lactobacillus plantarum species identified as the Lactobacillus plantarum LP02 LMG P-21020 bacterium strain; and
(a-iv) a bacterium strain of the Lactobacillus rhamnosus species identified as the Lactobacillus rhamnosus LR06 DSM 21981 bacterium strain; and
(a-v) a bacterium strain of the Bifidobacterium ion gum species identified as the Bifidobacterium longum BL04 DSM 23233 bacterium strain; preferably at a weight ratio equivalent to 1:1:1:1, or equivalent to 1:1:1:1:1; preferably each strain being present at a concentration comprised between 1×108 CFU/AFU and 1×1012 CFU/AFU, with respect to the daily intake, preferably each strain being present at a concentration comprised between 1×109 CFU/AFU and 1×1011 CFU/AFU, with respect to the daily intake.

### Claim 4 (depends on 1)

The composition (C) for use according to claim 1, said composition (C) further comprises:
(c) at least one gum-bacterial strain combination selected from among a first group of gum-bacterial strain combinations, and/or
(d) at least one vitamin selected from among a second group of vitamins, and/or
(e) at least one salt selected from among a third group of organic and/or inorganic salts, and/or
(f) at least one substance selected from among a fourth group of antioxidant substances.

### Claim 5 (depends on 4)

The composition (C) for use according to claim 4, wherein said first group of gum-bacterial strain combinations comprises or, alternatively, consists of: (c-i) at least one natural vegetable gum such as tara gum and (c-ii) the S. thermophilus ST10 DSM 25246 bacteria strain; preferably the S. thermophilus ST10 DSM 25246 bacteria strain present at a concentration comprised between 1×108 CFU/AFU and 1×1012 CFU/AFU, with respect to the daily intake; preferably it is present at a concentration comprised between 1×109 CFU/AFU and 1×1011 CFU/AFU, with respect to the daily intake.

### Claim 6 (depends on 4)

The composition (C) for use according to claim 4, wherein said second group of vitamins comprises or, alternatively, consists of: (d-i) vitamins of group C, (d-ii) vitamins of group E, (d-iii) vitamins of group B and/or (d-iv) vitamins of group D; preferably each single vitamin being present at an amount equivalent to 100% RDA.

### Claim 7 (depends on 4)

The composition (C) for use according to claim 4, wherein said third group of organic and/or inorganic salts comprises or, alternatively, consists of: (e-i) organic and/or inorganic magnesium salts, (e-ii) organic and/or inorganic selenium salts and/or (e-iii) organic and/or inorganic zinc salts; preferably wherein said magnesium salt (e-i) is magnesium glycinate, said selenium salt (e-ii) is selenium methionine and said zinc salt (e-iii) is zinc gluconate; preferably each single salt being present at an amount equivalent to 100% RDA.

### Claim 8 (depends on 4)

The composition (C) for use according to claim 4, wherein said fourth group of antioxidant substances comprises or, alternatively, consists of: (f-i) N-acetyl cysteine (NAC), (f-ii) Coenzyme Q10 (CoQ10) and/or (f-iii) Acetyl-L-carnitine ALC; preferably each single antioxidant substance being present at an amount equivalent to 100 mg/day.

### Claim 9

A method for modulating the mood of a subject, comprising administering to the subject a composition (C) comprising or, alternatively, consisting of:
(a) a bacteria strains mixture (M) comprising or, alternatively, consisting of at least one bacteria strain selected from among the group comprising or, alternatively, consisting of:
(a-i) a bacterium strain of the Lactobacillus fermentum species identified as the Lactobacillus fermentum LF16 DSM 26956 bacterium strain,
(a-ii) a bacterium strain of the Lactobacillus plantarum species identified as the Lactobacillus plantarum LP01 LMG P-21021 bacterium strain,
(a-iii) a bacterium strain of the Lactobacillus plantarum species identified as the Lactobacillus plantarum LP02 LMG P-21020 bacterium strain,
(a-iv) a bacterium strain of the Lactobacillus rhamnosus species identified as the Lactobacillus rhamnosus LRO6 DSM 21981 bacterium strain; and
(a-v) a bacterium strain of the Bifidobacterium longum species identified as the Bifidobacterium longum BL04 DSM 23233 bacterium strain; and, optionally,
(b) at least one technological additive and/or at least one pharmaceutical or food grade excipient, to facilitate mood modulation in a subject.

### Claim 10 (depends on 9)

The method of claim 9, wherein said (a) bacteria strains mixture (M) comprises or, alternatively, consists of:
(a-i) a bacterium strain of the Lactobacillus fermentum species identified as the Lactobacillus fermentum LF16 DSM 26956 bacterium strain; and
(a-ii) a bacterium strain of the Lactobacillus plantarum species identified as the Lactobacillus plantarum LP01 LMG P-21021 bacterium strain, and/or;
(a-iii) a bacterium strain of the Lactobacillus plantarum species identified as the Lactobacillus plantarum LP02 LMG P-21020 bacterium strain; and
(a-iv) a bacterium strain of the Lactobacillus rhamnosus species identified as the Lactobacillus rhamnosus LR06 DSM 21981 bacterium strain; and
(a-v) a bacterium strain of the Bifidobacterium longum species identified as the Bifidobacterium longum BL04 DSM 23233 bacterium strain; preferably at a weight ratio equivalent to 1:1:1:1, or equivalent to 1:1:1:1:1; preferably each strain being present at a concentration comprised between 1×108 CFU/AFU and 1×1012 CFU/AFU, with respect to the daily intake, preferably each strain being present at a concentration comprised between 1×109 CFU/AFU and 1×1011 CFU/AFU, with respect to the daily intake.

### Claim 11 (depends on 9)

The method of claim 9, wherein said composition (C) further comprises:
(c) at least one gum-bacterial strain combination selected from among a group of gum-bacterial strain combinations; preferably wherein said first group of gum-bacterial strain combinations comprises or, alternatively, consists of: (c-i) at least one natural vegetable gum such as tara gum and (c-ii) the S. thermophilus bacteria strain ST10 DSM 25246; preferably S. thermophilus bacteria strain ST10 DSM 25246 is present at a concentration comprised between 1×108 CFU/AFU and 1×1012 CFU/AFU, with respect to the daily intake; preferably it is present at a concentration comprised between 1×109 CFU/AFU and lx1011 CFU/AFU, with respect to the daily intake; and/or
(d) at least one vitamin selected from among a second group of vitamins; preferably wherein said second group of vitamins comprises or, alternatively, consists of: (d-i) vitamins of group C, (d-ii) vitamins of group E, (d-iii) vitamins of group B and/or (c-iv) vitamins of group D; and/or
(e) at least one salt selected from among a third group of organic and/or inorganic salts; preferably wherein said third group of organic and/or inorganic salts comprises or, alternatively, consists of: (e-i) magnesium organic and/or inorganic salts, (e-ii) selenium organic and/or inorganic salts and/or (e-iii) zinc organic and/or inorganic salts; preferably wherein said magnesium salt (e-i) is magnesium glycinate, said selenium salt (e-ii) is selenium methionine and said zinc salt (e-iii) is zinc gluconate; and/or
(f) at least one substance selected from among a fourth group of antioxidant substances; preferably wherein said fourth group of antioxidant substances comprises or, alternatively, consists of: (f-i) N-acetyl cysteine (NAC), (f-ii) Coenzyme Q10 (CoQ10) and/or (f-iii) acetyl-L-carnitine ALC.
